Home LiteratureArticle Details

PMID: 1796300 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.

Seminars in thrombosis and hemostasis ·Vol. 17 ·No. 3 ·1991-07-00 ·Pages 303-12

Jänicke F, Schmitt M, Graeff H

Abstract

暂无摘要

MeSH Terms

Breast Neoplasms/chemistry,mortality Female Humans Immunohistochemistry Neoplasm Recurrence, Local/metabolism Plasminogen Inactivators/analysis Predictive Value of Tests Prognosis Survival Rate Tissue Plasminogen Activator/analysis Urokinase-Type Plasminogen Activator/analysis

Chemicals

Plasminogen Inactivators Tissue Plasminogen Activator Urokinase-Type Plasminogen Activator

Authors & Affiliations

3 authors, click to expand affiliations / ORCID

Jänicke F

Frauenklinik der Technischen Universität München, Klinikum rechts der Isar, Germany.

Schmitt M

Graeff H

Article Info

Journal

Seminars in thrombosis and hemostasis

Abbr.

Semin Thromb Hemost

ISSN

0094-6176

DOI

10.1055/s-2007-1002624

Published

1991-07-00

Pages

303-12

Language

English

Region

United States

NLM ID

0431155

Subset

External Links

PubMed source DOI: 10.1055/s-2007-1002624 View journal details

Analysis Services

Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.

Contact

WeChat Official Account